COVID-19 is being developed by Profectus BioSciences Inc in US, which was acquired by Aurobindo Pharma's subsidiary Auro Vaccines LLC.
According to Govindarajan, the company's viral vaccine manufacturing capacity in India would be undertaken in two phases. The first phase would be ready by October and the commercial facility by March, next year."So on the VSV platform, they (Auro Vaccines) are already developing a COVID-19 vaccine as well and we are creating the capacity in India wherein there are two phases of capacity.
The first set of capacity would be ready by October, where we would like to make the product and start the Phase-I and Phase-II by the end of the year.""And our commercial facility, we are aiming to get it ready by around.